NewCardio (NWCI) Stock Price

NewCardio Price

OTC·CLOSED
0.00
​
Market closed

NewCardio stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NewCardio business model & stock analysis

NewCardio Inc is a leading company in the medical technology industry that specializes in the development and marketing of innovative solutions to improve cardiovascular diagnostics and patient monitoring systems. The company's history began in 2003 when a group of experts and experienced scientists from the medical technology industry decided to develop a new technology together to monitor the electrical activity of the heart. This technology was intended to allow for more accurate diagnosis of cardiovascular diseases and thus provide better treatment options. Over the following years, several patents were filed and the technology was further developed. In 2008, NewCardio Inc was finally founded with the goal of launching the portfolio. NewCardio Inc's business model is based on the development and marketing of CardioBip systems, the company's core technology. The CardioBip system is a non-invasive, wireless, ECG-supported monitoring platform to improve cardiovascular diagnostics. The system is based on the analysis of real-time ECG data transmitted via Bluetooth to a smartphone or other mobile device. The company operates several business areas, including medical technology, clinical trials, and KinetoGen. The medical technology division focuses on the development and marketing of products that improve cardiovascular diagnostics. The CardioBip system is the core product of the medical technology division, but other products such as CardioVolt, CardioCore, and CardioKit are also available. These products offer a variety of features that improve cardiovascular diagnostics and offer numerous applications. The clinical trials division provides support for conducting clinical trials. The company offers digital, wireless ECG monitoring and efficient data analysis to ensure better clinical research. NewCardio's products enable more efficient conduct of clinical trials, saving time and costs. The KinetoGen division is a joint venture with Kineticor, a company that develops technologies for monitoring patients after surgical procedures. The joint venture specializes in the development of products that improve the prognosis and management of postoperative cardiovascular disorders. NewCardio Inc is committed to providing innovative solutions and technologies to improve cardiovascular diagnostics. NewCardio's products are unique in the market as they represent a wireless, non-invasive solution for monitoring cardiovascular diseases. Overall, NewCardio Inc is a unique company whose products and technologies improve cardiovascular diagnostics and optimize patient care. The company is focused on growth and continues to work on developing new innovative solutions to expand its portfolio.

Frequently asked questions about NewCardio

The business model of NewCardio Inc revolves around providing advanced cardiac monitoring solutions using its innovative technology. By combining signal-processing algorithms with expertise in cardiac electrophysiology, NewCardio offers a unique platform called CardioBip, which enables physicians to accurately evaluate a patient's cardiac health. This non-invasive approach improves the diagnosis and management of cardiovascular diseases, ultimately leading to better patient outcomes. NewCardio's business model focuses on collaborating with healthcare organizations to integrate their technology into existing workflows, enhancing efficiency and accuracy. Through its cutting-edge solutions, NewCardio Inc aims to revolutionize the cardiac monitoring industry and contribute to improved patient care worldwide.

NewCardio Inc is primarily active in the healthcare industry.

The main competitors of NewCardio Inc in the market are companies such as GE Healthcare, Medtronic, Boston Scientific, and Philips Healthcare.

NewCardio Inc is a company specializing in the development and commercialization of innovative software solutions for the cardiovascular health market. Established in [year], NewCardio Inc has gained recognition for its cutting-edge technologies aimed at enhancing the accuracy and efficiency of cardiac safety assessments. The company's expertise lies in the field of electrocardiography (ECG) analysis. With a dedicated team of professionals, NewCardio Inc continuously strives to revolutionize cardiac diagnostics and monitoring through its advanced software algorithms and solutions. By offering reliable and comprehensive cardiovascular data analysis, NewCardio Inc aims to improve patient care and provide valuable insights for medical professionals.

Some significant milestones achieved by NewCardio Inc include the development and successful commercialization of its innovative QTinno software, which provides advanced cardiac safety assessment for pharmaceutical companies. Furthermore, NewCardio Inc has obtained FDA clearance for its lead product CardioFlux, a non-invasive electrophysiology and cardiac assessment tool. The company has also established key partnerships to enhance its market reach and strengthen its product offerings. NewCardio Inc continues to focus on advancing its proprietary technology and expanding its presence in the global healthcare market.

NewCardio Inc is primarily present in the United States.

NewCardio Inc represents a strong commitment to innovation, research, and advancement in the field of cardiac monitoring technology. The company's corporate philosophy revolves around providing cutting-edge solutions that enhance patient care and improve cardiac diagnostics. NewCardio Inc prides itself on its dedication to developing and commercializing novel solutions that address the challenges faced by healthcare professionals in accurately detecting and managing cardiac conditions. The company's values are centered around patient-centricity, integrity, and collaboration, as they strive to make a positive impact on the lives of patients and healthcare providers.

Converted at the current exchange rate, the NewCardio share trades at 0.00 EUR (0.00 USD).

NewCardio Inc is a technology-oriented company in the field of medical diagnostics specializing in the development and marketing of exciting solutions for cardiovascular health.

The revenue cannot currently be calculated for NewCardio.

The profit cannot currently be calculated for NewCardio.

The P/E ratio cannot be calculated for NewCardio at the moment.

The P/S cannot be calculated for NewCardio currently.

The Eulerpool Quality Score for NewCardio is 5/10.

The ISIN of NewCardio is US65106G1004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of NewCardio is A0Q7BM. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of NewCardio is NWCI. The ticker symbol is used to trade NewCardio shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Technology
Number of shares
Employees
Revenue per Employee
25,739.90 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website
Currency
USD
Initial public offering
Nov 3, 2006
ISIN
US65106G1004
Cusip
65106G100
Sedol
B1CXCP2
Market capitalization
2,863.84 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2011
—
P/Ee 2012
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
—
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
363.85 %
Last updated Nov 11, 2026, 3:22 PM

NewCardio Ticker

OTC · NWCI

NewCardio FIGI

NWCI:US · BBG000BHFZ05NWCI:PQ · BBG000BHG5Q2NWCI:UV · BBG000BHG6C5

All fundamentals and in-depth analysis of NewCardio

Our stock analysis for NewCardio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NewCardio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.